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Conclusion 
• Despite overall good knowledge of ART, many second-line patients had limited understanding of viral load and its relationship to adherence and treatment failure. 
• Health workers need training on explaining the relationship between viral load, adherence and treatment failure to patients. Better explanations of these 
relationships can support adherence for some patients. 
• Counselling messages need to be i) patient-centered, ii) convey correct information, and iii) focus on problem-solving and identify strategies to address persistent 
adherence barriers, rather than blaming patients’ social and sexual behaviors for treatment failure. 
• Site differences in treatment literacy and virological failure can be explained by social, contextual and programmatic differences. 
• Study limitations include potential site-specific differences in administration of the survey questionnaires and social desirability bias in patients’ responses. Efforts 
were taken to reduce this through fieldworker training and for the qualitative component, use of repeated interviews to build rapport with participants. 
 
 
 
 
 
Background 
 
Médecins sans frontières (MSF) supports HIV care and treatment 
programs in: 
• Kenya: Homa Bay District Hospital (rural setting, some mobility among 
the population for fishing); 
• Malawi: Chiradzulu district hospital and 10 health facilities (rural setting, 
some mobility for employment in nearby Blantyre);  
• Mozambique: Maputo at a referral center for complex cases and 
second-line antiretroviral therapy (ART) (urban setting, mobile 
population). 
• The number of patients requiring second- and third-line antiretroviral 
therapy (ART) regimens is increasing in these programs 
• Understanding of the elements on which to base adherence 
interventions for these treatment-experienced patients is limited 
• A cross-sectional study on virological failure and drug resistance was 
conducted  in Nov 2014-Dec 2015 among patients ≥ 5 years receiving 
second-line ART since ≥ 6 months in the 3 programs. A qualitative 
component explored influences on ART adherence. 
Aim: As part of this study we investigated patients’ understanding 
of the relationship between treatment failure, viral load and 
adherence among those on 2nd and 3rd line ART regimens in MSF 
supported programmes in Kenya, Malawi and Mozambique. 
Methods 
 
Quantitative:  
• During the cross-sectional study, a structured questionnaire was 
administered to assess knowledge on ART and viral load (VL). 
Data shown here are for patients ≥ 18 years (87% of total 
surveyed). 
• ART knowledge was assessed with 9 true/false questions. Good 
knowledge was defined as 7 of 9 answered correctly. 
• Knowledge of VL was ascertained via two non-probed, pre-coded 
questions. 
 
Qualitative: 
• ~12 months after the cross-sectional assessment, repeated in-
depth interviews (IDIs) were conducted per site with 13-16 
patients, purposively sampled from survey participants ensuring 
diversity in VL outcomes, adapted ART regimens (second and 
third-line), age and sex 
• IDIs were also held with 5 health workers per site 
• IDIs were recorded, transcribed and translated into English for 
coding 
• Content analysis was used to identify emergent themes explaining 
patients’ understanding of viral load and adherence. 
 
 
Results (quantitative) 
N=700 adult participants interviewed: Kenya 299 (51% female);  
    Malawi 212 (59% female); Mozambique 198 (58% female). 
• ART knowledge: was good in all sites, notably high in Malawi. 
• VL knowledge: Can you explain what a VL test is for? (non-probed) 
o Don’t know 
 19% (Kenya), 15% (Malawi), 32% (Mozambique)  
o VL test checks if VL is undetectable/measures VL   
 67% (Kenya), 73% (Malawi), 55% (Mozambique)  
o VL  test checks if the ARV treatment still works  
    21% (Kenya), 66% (Malawi), 5% (Mozambique)  
o VL  test checks if I am taking the ARV treatment  
     4% (Kenya), 38% (Malawi), 1.6% (Mozambique). 
• Mostly no association found between virological failure (VL ≥ 1000 copies/ml) and knowledge about ART or VL testing (table 1). 
• Overall, knowledge of ART and VL was lower in the Mozambique site.  
• Accurate knowledge of ART and its 
relationship to VL can help motivate 
some patients to adhere to ART.  
 
 
 
 
• However, good understanding of ART 
and VL results are not sufficient for 
good adherence. Other individual-level 
and context-specific factors (e.g. 
stigma, poverty, mobility) and health 
systems issues undermined regular 
pill-taking and varied between sites. 
 
 
 
• Adherence intentions improved for 
some patients after switching 
regimens, but poor adherence 
remained a risk if previous challenges 
were not continuously addressed. 
 
Table 1: Patient knowledge of ART and VL testing by virological outcome and site 
Figure 1: 
study sites  
 
• Counseling was a source of both 
correct and incorrect knowledge 
about ART and VL among patients in 
this study.  
 
 
 
• Moralistic messages from staff in all 
sites meant some patients believed 
that detectable VL and treatment 
failure were due to unprotected sex, 
drinking alcohol, smoking, or using 
traditional medicine. These patients 
did not explicitly link their VL results 
to their pill-taking, which could 
undermine their adherence. 
 
• Good quality individual or group 
counselling was important for helping 
patients to understand ART and VL 
results, as well as giving them the 
morale to maintain pill-taking. 
 
 
 
“If one uses condoms  the virus would 
die because I hear the virus’ food are 
the sperms so it is like we are feeding 
them, so smoking, condomising, stress, 
good nutrition, how you work; how you 
work affects how the medicine works.. 
Don’t work a lot…! Where did you hear 
that HIV virus eats sperm? At the 
hospital, from counsellors”  
[Man, 3rd line ART, Malawi] 
“I got shocked because when I was joining 
third line, I was told the amount of my CD4 and 
my viral load…so it is in my mind that I have to 
adhere to them (ART) well the way I am told, 
and if I break …that’s where my life ends.”   
[Man, 3rd line ART, Kenya] 
“Only one of the twins survived…I had 
a lot of thoughts, I stopped taking drugs 
for 2 years. [name of counsellor] kept 
on teaching us…I joined the support 
group and you could hear people had 
challenges more than what you are 
going through, I listened to them then I 
gathered courage and started taking 
drugs.” [Woman, 2nd line ART, Kenya] 
  
“I sometimes have appetite of eating fruits, 
many other things. Nonetheless I can’t afford 
[them]… the same difficulties I used to go 
through when I was on the first line. Regarding 
difficulties, nothing has changed.  Just to have 
something to eat is a big problem.” [Man 2nd 
line ART, Mozambique] 
“Sometimes they miss their appointments.. 
because of the finances, they can not be able 
to reach the hospital, at times they come late 
because of the terrains. At times the reception 
[at the hospital] is not welcoming to them… 
they are seen as people who are rejects….Yah 
so those are some of the reports that clients 
give. And at times they lament the long 
queues. “[Health worker, Kenya] 
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  VL [copies/ml] VL [copies/ml] VL [copies/ml] 
Participants n (%) <1000   ≥1000 p value      <1000  
            
≥1000 p value      <1000   ≥1000 
 
p value 
Total surveyed 256 (86) 43 (14) n/a 
 
188 (89) 24 (11) n/a 144 (76) 45 (24) 
 
n/a 
Good ART knowledge:  (8/9 questions correct) 192 (75) 31 (72) 0.68 
 
186 (99)  24 (100) 0.61 94 (65) 20 (44) 
 
0.013 
Doesn’t know if ever had VL test  39 (15) 9 (20) 0.56 
 
9 (5) 1 (4) 0.64 26 (18) 11 (24) 
 
0.37 
Can you explain what is a viral load test/ what it is good for?                           
(Non-probed, replies were coded into the following categories)       
  
        
  
    Don't know 43 (17) 15 (35) <0.01 28 (15) 4 (17) 0.76 45 (31) 16 (36) 0.57 
    To check if the viral load is undetectable/measure viral load 179 (70) 23 (53) 0.033 135 (72) 20 (83) 0.23 83 (57) 21 (47) 0.21 
    To check if the ARV treatment still works  57 (22) 7 (16) 0.37 122 (65) 17 (71) 0.56 6 (4) 4 (9) 0.21 
    To check if I am taking the ARV treatment  11 (4)   0 (0) n/a 72 (38) 9 (36) 0.94 1 (0.7) 2 (4) 0.14 
Acknowledgements:  
We would like to thank all of the participants, fieldworkers and  
MSF field teams  for their support and contributions to the study.  
Contact: Birgit.Schramm@epicentre.msf.org 
 
 
